Skip to main content
SpringerLink
Log in

A case for reclassifying infiltrating gliomas in adults

  • Letter to the Editor
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Louis D, Ohgaki H, Wiestler O, Cavenee W (eds) (2007) WHO classification of tumors of the central nervous system. IARC, Lyon

    Google Scholar 

  2. Schramm J (ed) (2010) Low-grade gliomas. Springer, New York

    Google Scholar 

  3. von Deimling A (ed) (2009) Gliomas. Springer, Heidelberg

    Google Scholar 

  4. Bourne TD, Schiff D (2010) Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 6:695–701

    Article  PubMed  Google Scholar 

  5. Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD, Murphy KM (2006) Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 65:988–994

    Article  PubMed  Google Scholar 

  6. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861

    Article  PubMed  CAS  Google Scholar 

  7. Vogazianou AP, Chan R, Backlund LM, Pearson DM, Liu L, Langford CF, Gregory SG, Collins VP, Ichimura K (2010) Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neurooncology 12:664–678

    Google Scholar 

  8. Rostomily RC, Born DE, Beyer RP, Jin J, Alvord EC Jr, Mikheev AM, Matthews RT, Pan C, Khorasani L, Sonnen JA, Montine TJ, Shi M, Zhang J (2010) Quantitative proteomic analysis of oligodendrogliomas with and without 1p/19q deletion. J Proteome Res 9:2610–2618

    Article  PubMed  CAS  Google Scholar 

  9. Ferrer-Luna R, Mata M, Nunez L, Calvar J, Dasi F, Arias E, Piquer J, Cerda-Nicolas M, Taratuto AL, Sevlever G, Celda B, Martinetto H (2009) Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression. J Neurooncol 95:343–354

    Article  PubMed  CAS  Google Scholar 

  10. Marko NF, Prayson RA, Barnett GH, Weil RJ (2010) Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study. Genomics 95:16–24

    Article  PubMed  CAS  Google Scholar 

  11. Scheie D, Cvancarova M, Mork S, Skullerud K, Andresen PA, Benestad I, Helseth E, Meling T, Beiske K (2008) Can morphology predict 1p/19q loss in oligodendroglial tumours? Histopathology 53:578–587

    Article  PubMed  CAS  Google Scholar 

  12. Kanner AA, Staugaitis SM, Castilla EA, Chernova O, Prayson RA, Vogelbaum MA, Stevens G, Peereboom D, Suh J, Lee SY, Tubbs RR, Barnett GH (2006) The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg 104:542–550

    Article  PubMed  Google Scholar 

  13. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381–1393

    Article  PubMed  CAS  Google Scholar 

  14. Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M (2008) Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18:520–532

    PubMed  CAS  Google Scholar 

  15. Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN (2009) Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 68:1319–1325

    Article  PubMed  CAS  Google Scholar 

  16. Wiwanitkit V (2009) Correspondence regarding: diagnostic utility of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 68:1319–1325. J Neuropathol Exp Neurol 69:320; author reply 320–321, 2010

    Google Scholar 

  17. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599–601

    Article  PubMed  CAS  Google Scholar 

  18. Myal Y, Del Bigio MR, Rhodes RH (2003) Age-related differences in 1p and 19q deletions in oligodendrogliomas. BMC Clin Pathol 3:6

    Article  PubMed  Google Scholar 

  19. Labussiere M, Idbaih A, Wang XW, Marie Y, Boisselier B, Falet C, Paris S, Laffaire J, Carpentier C, Criniere E, Ducray F, El Hallani S, Mokhtari K, Hoang-Xuan K, Delattre JY, Sanson M (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74:1886–1890

    Article  PubMed  CAS  Google Scholar 

  20. Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K, Wang XW, Loundou A, Chapon F, Pineau S, Ouafik L, Chinot O, Figarella-Branger D (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719–729

    Article  PubMed  Google Scholar 

  21. Pollack MM, Patel KM (2005) The volume-outcome relationship in pediatric intensive care units: a conceptual advance or a statistical novelty? Pediatr Crit Care Med 6:227–228

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

NFM is supported in part by a grant from the American Association of Neurological Surgeons’ William P. VanWagenen Fellowship program. RJW is supported in part by the Melvin Burkhardt Chair in Neurosurgical Oncology and by the Karen Colina Wilson research endowment within the Brain Tumor and Neuro-oncology Center at the Cleveland Clinic Foundation.

Author information

Authors and Affiliations

  1. Cambridge University, Cambridge, UK

    Nicholas F. Marko & Robert J. Weil

Authors
  1. Nicholas F. Marko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert J. Weil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas F. Marko.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marko, N.F., Weil, R.J. A case for reclassifying infiltrating gliomas in adults. J Neurooncol 109, 587–591 (2012). https://doi.org/10.1007/s11060-012-0928-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-012-0928-y

Keywords

Search

Navigation